by Paul McIntosh | Jul 7, 2020 | Press Releases
NovaBiotics are delighted to announce that our latest publication is accessible from today. Teamwork focused on solutions to antimicrobial resistance with our collaborators – Marcelo Der Torossian Torres, University of Pennsylvania Cesar de la Fuente, University...
by Paul McIntosh | Apr 13, 2020 | Press Releases
NovaBiotics, the clinical stage antimicrobials drug discovery company, announces the rapid repurposing of Nylexa for the ‘hidden killer’ underlying COVID-19: secondary bacterial lung infections. Nylexa ‘supercharges’ antibiotics, boosting their efficacy against...
by Paul McIntosh | Mar 31, 2020 | Press Releases
NovaBiotics announces its latest peer-reviewed publication describing data confirming the stand-out properties of Novexatin® (NP213), NovaBiotics’ brush-on treatment for fungal nail infection (onychomycosis). The paper, “NP213 (Novexatin®): A unique therapy candidate...
by novabioticsadm1n | Mar 19, 2020 | 2020, Press Releases
Date posted: March 19, 2020 NovaBiotics are attending the 4th Antimicrobial Resistance (AMR) Conference (Novel Antimicrobials & AMR Diagnostics) on 24-25 August 2020. The event is taking place in Basel, Switzerland and we will be joining 400 international AMR...
by novabioticsadm1n | Mar 19, 2020 | 2020, Press Releases
Date posted: March 19, 2020 COVID-19 NovaBiotics is now mobilising. We are exploring the potential of some of our drug candidates as rapidly deployable solutions to the respiratory bacterial infections associated with COVID-19 and other coronavirus/respiratory...
by novabioticsadm1n | Mar 19, 2019 | 2019, Press Releases
Date posted: March 19, 2020 Three Posters on New Lynovex Preclinical and Clinical Data to be presented at NACFC, 31st October to 2nd November 2019, Nashville Tennessee. Dr Douglas Fraser-Pitt will present three posters on Thursday 31st October 2019...
Contact Us
Technology
Therapeutic Focus
News and Events
Recent Comments